Bluejay IPO Presentation Deck

Bluejay is Focused on Improving Patient Outcomes in Hospital/LTAC* Settings Using Symphony, a cost efficient, rapid, near-patient product for triage, diagnosis and monitoring of disease progression Key Investment Highlights Physicians need high-sensitivity near-patient testing for triage/treatment guidance in critical care settings Symphony System has the potential to enable physicians to make better treatment decisions IL-6 Test for Sepsis Triage leads a pipeline targeting a potential multi-billion-dollar market opportunity Marketed in Japan for 3years by collaborator Toray** as "Research Use Only" product FDA 510(k) application for the IL-6 Test for Sepsis Triage planned for late Q3:22 bluejay LTAC-Long Term Acute Care "Toray Industries, Inc. Plan to expand the testing menu to include other well- validated critical care biomarkers Developed by Toray** through an extensive 12-year program & Bluejay has exclusive ex-Japan global rights Attractive recurring revenue model and a focused marketing plan to support the launch Led by a Team of healthcare and diagnostics veterans IPO proceeds to support development and marketing of IL-6 for Sepsis Triage Copyright 2021 Blunjay Diagnostics, Inc. All rights reserved in all slides | October 2021 5

View entire presentation